Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Reckitt Benckiser (Australia) Pty Ltd

Overview

The Therapeutic Goods Act 1989 (TGA Act) was enacted to regulate therapeutic goods in Australia, ensuring that they are of acceptable quality, safety, and efficacy. It was introduced to address the need for a comprehensive framework governing the manufacturing, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Therapeutic Goods Administration (TGA), operating under the Department of Health, administers the Act, with its primary policy objective being the protection of public health by ensuring that therapeutic goods available in Australia meet appropriate standards. In the instance referenced, the TGA granted consent under sections 14 and 14A of the Act for the supply of certain antifungal products that did not fully comply with labelling requirements, reflecting the TGA's role in balancing regulatory compliance with practical considerations in the therapeutic goods market. This particular instance illustrates how the TGA operates within the Act to manage specific issues that arise in the supply chain of therapeutic goods, ensuring that any potential risks to public health are mitigated while also facilitating the availability of necessary treatments. The consent provided by the TGA allows for a temporary exemption from certain regulatory requirements, highlighting the administrative flexibility embedded in the Act to address unique circumstances while maintaining overall public health protections.

Scope and Application

The Therapeutic Goods Act 1989 applies to therapeutic goods, including medicines, medical devices, and other related products, and covers their regulation across the Commonwealth of Australia. This Act encompasses a wide range of entities, including manufacturers, importers, sponsors, and suppliers of therapeutic goods, as well as individuals who engage in the supply of these goods within the country. The Act sets out the requirements for the approval, registration, and labelling of therapeutic goods, and it also outlines the offences and penalties related to non-compliance. The Act's application is broad and includes both direct and indirect supply of therapeutic goods, which means it applies to a variety of industries and transactions. Geographically, the Act applies nationally across Australia, covering all states and territories. There may be exclusions or exemptions specified in subordinate instruments, but the primary application of the Act is comprehensive and inclusive of the therapeutic goods industry. In the specific case of the consent granted under sections 14 and 14A of the Therapeutic Goods Act 1989, the application involves the correction of labelling errors on certain products supplied by Reckitt Benckiser (Australia) Pty Ltd. The consent allows for the supply of Scholl tinea powder spray, Eulactol antifungal spray, and Scholl tinea liquid spray with labels that do not conform to the current sponsor's details, as specified in Therapeutic Goods Order No. 69. This consent is effective for a limited period, from 8 September 2015 until 30 April 2016, and is a temporary measure to allow for the correction of specific non-compliance issues while ensuring that the therapeutic goods remain available to the public. This case highlights the Act's role in facilitating adjustments to regulatory requirements in specific situations, thereby maintaining the balance between regulatory compliance and practical supply needs.

Key Provisions

The Therapeutic Goods Act 1989, particularly sections 14 and 14A, provides a framework through which certain therapeutic goods can be supplied despite not fully adhering to all regulatory requirements. In this instance, sections 14 and 14A were invoked by the Secretary of the Department of Health to allow for the supply of three specific products: Scholl Tinea Powder Spray (AUST R 13519), Eulactol Antifungal Spray (AUST R 55567), and Scholl Tinea Liquid Spray (AUST R 13520). These products do not comply with the label requirements stipulated in paragraph 3(2)(l) of Therapeutic Goods Order No. 69, which governs the general requirements for labels for medicines. The non-compliance stems from the labels containing the name and address details of the previous sponsor, SSL Australia Pty Ltd, rather than the current sponsor, Reckitt Benckiser Pty Ltd. The obligations imposed by this consent require that the products be supplied with the specified labels, which include outdated sponsor information. The consent mandates that this non-compliant labelling be used for the period from 8 September 2015 until 30 April 2016. This period is crucial, as it delineates the timeframe within which the non-compliant labels must be used and ensures that the products are supplied correctly during this interval. Breach of the conditions set by this consent could lead to legal repercussions. The Therapeutic Goods Act 1989 stipulates various offences and penalties for non-compliance with its provisions. Although specific penalties for this consent are not detailed in the text, general provisions under the Act allow for substantial fines and potential imprisonment for serious breaches. For instance, supplying therapeutic goods that do not comply with the Act can result in fines up to $1,650,000 for a corporation and imprisonment for up to 10 years for an individual. These severe penalties underscore the importance of adhering to the terms of the consent and ensuring that all therapeutic goods are supplied in accordance with the Act's requirements.